drugset / Trial / NCT00284128

AVE7688 in Patients With Mild to Moderate Blood Pressure

NCT00284128

Phase 2/3 Completed 1940 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from baseline in trough diastolic blood pressure at the end of week 12. The secondary objectives are: * To assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from baseline in trough systolic blood pressure at the end of week 12 * To compare the percentages of responders after 12 week of treatment * To evaluate the long term safety and tolerability of AVE 7688 with particular attention to angioedema

Timeline

Start
2005-12
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ILEPATRIL Small molecule 2.5 mg Oral
Subject ILEPATRIL Small molecule 10 mg Oral
Subject ILEPATRIL Small molecule 35 mg Oral
Subject ILEPATRIL Small molecule 50 mg Oral
Subject Losartan Other / unclassified 100 mg Oral

Indications